NCT03681392 (S4S4BPH/ED) is a NA clinical trial of Dr. Pyke's Supplement for Stream (S4S) in Prostatism, sponsored by Robert E. Pyke.

Who is sponsoring NCT03681392?

NCT03681392 is sponsored by Robert E. Pyke.

What drugs are being tested in NCT03681392?

Interventions in NCT03681392: Dr. Pyke's Supplement for Stream (S4S).

What condition does NCT03681392 study?

NCT03681392 studies Prostatism, Erectile Dysfunction.

Is NCT03681392 still recruiting?

NCT03681392 is currently withdrawn. Last updated 4 December 2021.

Last reviewed 2021-12-04 · How we verify

NCT03681392: S4S4BPH/ED

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Open-label Randomized Crossover Dose-finding Study of the Efficacy, Safety, and Tolerability of Dr. Pyke's Supplement for Stream (S4S) in Older Men With Lower Urinary Tract Symptoms and/or Sexual Dysfunction

Withdrawn NA Last updated 4 December 2021

What this trial tests

NA trial testing Dr. Pyke's Supplement for Stream (S4S) in Prostatism. Withdrawn.

Timeline

1 January 2021

Primary endpoint
1 December 2022

1 March 2023

Quick facts

Lead sponsor	Robert E. Pyke
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	supportive care
Start date	1 January 2021
Primary completion	1 December 2022
Estimated completion	1 March 2023

Drugs / interventions tested

Dr. Pyke's Supplement for Stream (S4S)

Conditions studied

Prostatism — all drugs for Prostatism →
Erectile Dysfunction — all drugs for Erectile Dysfunction →

Sponsor

Robert E. Pyke

Who can join

40 and older, male only, with Prostatism or Erectile Dysfunction. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

International Prostate Symptom Score (IPSS)
Time frame: 1-4 weeks
measure of lower urinary tract symptoms in men with prostatism, total score; 0=best possible (no symptoms); 35 = worst possible; mean change and number of patients 50% improved
Primary safety outcome: adverse events
Time frame: 1 week
Reports from subjects of new or worse symptoms; number of patients with any adverse event, count and % of patients with each type of such adverse events

Sponsor's own description

This is the first clinical trial of Dr. Pyke's Supplement for Stream (S4S), a proprietary combination of Panax ginseng extract, L-citrulline, beta-sitosterol and vitamin D3, to investigate its effects on prostatism and erections, and its tolerability, when taken daily and twice-daily for 2 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03681392 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Robert E. Pyke
Last refreshed: 4 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03681392.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing